November 29, 2016 - By whatsonthorold
Joseph Turk, an insider and also President of the leading company Nxstage Medical Inc made trade. He unloaded 12,169 shares of the firm with Joseph Turk’s stock sale worth approx. $316,485 US Dollars – totalled based on $26.0 for each share. He also sold 23,500 shares that are worth about $616,820 USD in the last 30 days. The probability of this sell staying undiscovered is extremely low, with the President currently holding 79,780 shares —- that is 0.12% of the total market cap of Nxstage Medical Inc.
Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. $30 is the highest target while $14 is the lowest. The $23.10 average target is -10.43% below today’s ($25.79) stock price. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. BTIG Research initiated NxStage Medical, Inc. (NASDAQ:NXTM) rating on Friday, December 18. BTIG Research has “Buy” rating and $27 price target. Northland Capital upgraded NxStage Medical, Inc. (NASDAQ:NXTM) on Tuesday, June 28 to “Outperform” rating. The firm earned “Buy” rating on Friday, December 11 by Sterne Agee CRT. Piper Jaffray reinitiated it with “Overweight” rating and $18.50 target price in Thursday, March 31 report. Canaccord Genuity maintained NxStage Medical, Inc. (NASDAQ:NXTM) rating on Tuesday, August 2. Canaccord Genuity has “Buy” rating and $26 price target.
Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.23, from 0.97 in 2016Q1. The ratio improved, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.
Cortina Asset Mgmt Ltd Com, a Wisconsin-based fund reported 1.72 million shares. State Common Retirement Fund, a New York-based fund reported 81,881 shares. Osterweis Cap Mgmt owns 102,632 shares or 0.14% of their US portfolio. Essex Investment Mgmt Limited Co holds 51,459 shares or 0.19% of its portfolio. California State Teachers Retirement owns 133,515 shares or 0.01% of their US portfolio. First Light Asset Mgmt Llc accumulated 254,113 shares or 2.55% of the stock. Blackrock Japan has 0% invested in the company for 190 shares. Continental Advsr Ltd has invested 0.8% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Pnc Fincl Serv Grp Inc accumulated 0% or 383 shares. State Street last reported 1.04M shares in the company. Grp One Trading L P reported 375 shares or 0% of all its holdings. Blackrock owns 6,299 shares or 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,205 shares in its portfolio. Goldman Sachs holds 0% or 100,773 shares in its portfolio. Waddell Reed Fincl, a Kansas-based fund reported 222,718 shares.
Insider Transactions: Since September 12, 2016, the stock had 0 buys, and 8 insider sales for $1.41 million net activity. 3,000 shares were sold by MOORE CRAIG W, worth $69,930. Another trade for 1,000 shares valued at $25,970 was made by Turk Joseph E Jr on Thursday, November 17. $180,075 worth of NxStage Medical, Inc. (NASDAQ:NXTM) shares were sold by Burbank Jeffrey H. On Monday, November 21 the insider TOWSE MATTHEW W sold $112,789. 6,449 shares were sold by Giannini Daniel A, worth $167,416 on Monday, November 21. Swan Winifred L sold $76,530 worth of stock or 3,000 shares.
About 578,130 shares traded hands or 34.74% up from the average. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 62.58% since April 26, 2016 and is uptrending. It has outperformed by 57.32% the S&P500.
NxStage Medical, Inc. is a medical technology company. The company has a market cap of $1.65 billion. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. It currently has negative earnings. The Firm operates through three divisions: System One, In-Center and Services.
According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”
Analysts await NxStage Medical, Inc. (NASDAQ:NXTM) to report earnings on February, 8. They expect $-0.02 EPS, up 50.00% or $0.02 from last year’s $-0.04 per share.
More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016. Also Fool.com published the news titled: “Why NxStage Medical, Inc. Guided Lower Today” on February 10, 2016. Fool.com‘s news article titled: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” with publication date: August 04, 2016 was also an interesting one.
NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.